# Article information:

Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles - PMC  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608573/>

# Article summary:

1. The blood-brain barrier (BBB) is impermeable to biologics, making it difficult to deliver drugs to the brain.

2. Liposomes and other nanoparticles are good candidates for delivering biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner.

3. Experiments have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs, allowing for further transport across the BBB.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article “Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles” provides a comprehensive overview of the current research on targeted delivery of nanoparticles across the blood-brain barrier (BBB). The article is well written and provides a clear explanation of the various methods used to enable targeted uptake and transport of nanoparticles across the BBB. The authors provide evidence from independent research groups that demonstrate how antibodies targeting the transferrin receptor are superior for targeted delivery of nanoparticles to BECs, allowing for further transport across the BBB.

The article is reliable and trustworthy in its content, providing evidence from multiple sources to support its claims. The authors also provide detailed explanations on how specific proteins expressed by BECs enhance binding and uptake of antibodies from circulation, as well as how targeted nanoparticles can undergo specific binding and uptake when conjugated with weakened affinity or avidity antibodies. Furthermore, they discuss potential therapeutic uses of targeted nanoparticles in conditions with brain pathology.

The only potential bias in this article is that it focuses mainly on transferrin receptor-targeted liposomes, which may lead readers to believe that this is the only method available for transporting large molecules through the BBB. However, this bias does not detract from the overall reliability and trustworthiness of this article as it provides a comprehensive overview of current research on targeted delivery of nanoparticles across the BBB.

# Topics for further research:

* Blood-Brain Barrier Transport Mechanisms
* Non-Transferrin Receptor-Targeted Nanoparticles
* Brain Pathology Therapeutic Applications
* BBB Uptake Enhancing Proteins
* Nanoparticle Conjugation Strategies
* Avidity and Affinity Antibodies

# Report location:

<https://www.fullpicture.app/item/000fb639de9894883034b3c41711a17c>